CN116875513B - Pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver - Google Patents
Pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver Download PDFInfo
- Publication number
- CN116875513B CN116875513B CN202311047267.1A CN202311047267A CN116875513B CN 116875513 B CN116875513 B CN 116875513B CN 202311047267 A CN202311047267 A CN 202311047267A CN 116875513 B CN116875513 B CN 116875513B
- Authority
- CN
- China
- Prior art keywords
- product
- serum
- pediococcus acidilactici
- content
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000191998 Pediococcus acidilactici Species 0.000 title claims abstract description 89
- 210000004185 liver Anatomy 0.000 title claims abstract description 35
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 22
- 230000037356 lipid metabolism Effects 0.000 title claims abstract description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 66
- 230000001603 reducing effect Effects 0.000 claims abstract description 42
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 37
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 33
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- 230000001965 increasing effect Effects 0.000 claims abstract description 25
- 239000003613 bile acid Substances 0.000 claims abstract description 24
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 21
- 230000004060 metabolic process Effects 0.000 claims abstract description 10
- 210000003205 muscle Anatomy 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims description 71
- 241000287828 Gallus gallus Species 0.000 claims description 47
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000003674 animal food additive Substances 0.000 claims description 23
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000006870 function Effects 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 210000000579 abdominal fat Anatomy 0.000 claims description 14
- 230000000813 microbial effect Effects 0.000 claims description 14
- 210000002976 pectoralis muscle Anatomy 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 229940127557 pharmaceutical product Drugs 0.000 claims description 14
- 102000000019 Sterol Esterase Human genes 0.000 claims description 13
- 108010055297 Sterol Esterase Proteins 0.000 claims description 13
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 12
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 12
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 12
- 102000043296 Lipoprotein lipases Human genes 0.000 claims description 12
- 208000010706 fatty liver disease Diseases 0.000 claims description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 11
- 108010082126 Alanine transaminase Proteins 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 8
- 239000004575 stone Substances 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 229940026314 red yeast rice Drugs 0.000 claims description 5
- 241000193755 Bacillus cereus Species 0.000 claims description 4
- 241000193752 Bacillus circulans Species 0.000 claims description 4
- 241000193468 Clostridium perfringens Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 4
- 241000607715 Serratia marcescens Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 235000007189 Oryza longistaminata Nutrition 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 15
- 239000003833 bile salt Substances 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 12
- 239000002253 acid Substances 0.000 abstract description 9
- 244000144972 livestock Species 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 6
- 244000144977 poultry Species 0.000 abstract description 6
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 230000001276 controlling effect Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 66
- 230000002829 reductive effect Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 18
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 16
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 15
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 235000013330 chicken meat Nutrition 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000003307 slaughter Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 102000003914 Cholinesterases Human genes 0.000 description 7
- 108090000322 Cholinesterases Proteins 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 235000014590 basal diet Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 229940048961 cholinesterase Drugs 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000015784 hyperosmotic salinity response Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 102000017946 PGC-1 Human genes 0.000 description 3
- 108700038399 PGC-1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 3
- 229940046307 sodium thioglycolate Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000019735 mitochondria-nucleus signaling pathway Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
Abstract
The application provides pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver, wherein the pediococcus acidilactici is named pediococcus acidilactici (Pediococcus acidilactici) BLCC2-0326 and is preserved in China center for type culture collection (China, university of Wuhan, china) on the date of 2023, 07, and the preservation number is: cctccc NO: m20231310. The pediococcus acidilactici has good probiotics, has good acid and bile salt resistance, can degrade cholesterol and/or triglyceride in vitro, can be suitable for living environments in vivo, can play roles in regulating and controlling lipid metabolism, regulating and controlling bile acid metabolism, protecting liver, reducing blood lipid and increasing muscle and inhibiting bacteria, and has great development potential in the livestock and poultry healthy cultivation industry.
Description
Technical Field
The application relates to the field of microorganisms, in particular to pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver.
Background
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
Along with the improvement of national living standard, the demands of people on high-quality livestock and poultry products are increasing. On the one hand, the high pursuit of the growth speed of livestock and poultry leads to the improvement of the yield of meat products, but is accompanied by excessive fat deposition in animals, the modern commercial broiler breeds contain 150-200g of fat per kilogram of body weight, and most of fat is not necessary for physiology, so that not only is a lot of feed wasted, but also lipid metabolism disorder in the animals is caused, metabolic diseases such as fatty liver, ascites and the like are induced, the economic benefit of cultivation is seriously affected, and the food safety is also not facilitated. Fat deposition and lipid metabolism disorders have become critical issues that are currently in need of resolution in animal husbandry.
Research shows that various probiotics represented by lactobacillus and bifidobacterium can regulate intestinal microecological balance, regulate and control organism lipid metabolism and remodel the environment in the intestinal tract, thereby relieving the occurrence and development of metabolic syndrome. However, the probiotic strains are various, the physiological and biochemical characteristics of different species and even different strains are different, and the lipid-lowering capability of different hosts is also greatly different. It is necessary to screen probiotics which are suitable for in vivo living environment and can stably play a role in reducing lipid. Thus, more deeply controlled studies and clinical trials are required to establish specific therapeutic effects and dosages. The functional strain screening is developed, new functions of the strain are excavated, the strain utilization value can be improved, the technical problem of restricting the development of industry is solved, and technical guarantee is provided for healthy cultivation and food safety.
Disclosure of Invention
The invention provides a pediococcus acidilactici which is named as pediococcus acidilactici (Pediococcus acidilactici) BLCC2-0326, has good probiotics performance, is acid-resistant, bile salt-resistant, has good survival rate in artificial gastric juice and intestinal juice, can survive in an in-vivo environment well, has good in-vitro cholesterol and triglyceride degradation capacity and good antibacterial capacity, has excellent capacities of regulating and controlling lipid metabolism, regulating and controlling bile acid metabolism, protecting liver, preventing and/or treating hyperlipidemia, preventing and/or treating fatty liver and reducing blood lipid and increasing muscle in animal experiments, and has good application prospects.
Specifically, the invention provides the following technical scheme.
In a first aspect of the invention there is provided a strain of Pediococcus acidilactici designated Pediococcus acidilactici (Pediococcus acidilactici) BLCC2-0326 which has been deposited at the China center for type culture collection, university of Wuhan, gmbH, china, under the accession number: cctccc NO: m20231310.
In a second aspect of the invention there is provided the use of pediococcus acidilactici as described in the first aspect above for the preparation of a product for regulating lipid metabolism.
In some embodiments of the invention, the product is a pharmaceutical product, feed additive, microecological preparation or a microbial agent.
In some embodiments of the invention, the function of the product comprises at least one of:
(1) Reducing the Total Cholesterol (TC) content in serum;
(2) Reducing the content of Triglyceride (TG) in serum;
(3) Increasing the content of high density lipoprotein cholesterol (HDL-C) in serum;
(4) Reducing the content of Fatty Acid Synthase (FAS) in serum;
(5) Reducing the content of hydroxymethylglutaryl-coa reductase (HMGR) in the serum;
(6) Increasing the level of lipoprotein lipase (LPL) in the serum; and
(7) Increasing the level of Hormone Sensitive Lipase (HSL) in serum.
In a third aspect of the invention there is provided the use of pediococcus acidilactici as described in the first aspect above for the preparation of a product for regulating bile acid metabolism.
In some embodiments of the invention, the function of the product includes at least reducing the concentration of total bile acids in serum.
In some embodiments of the invention, the product is a pharmaceutical product, feed additive, microecological preparation or a microbial agent.
In a fourth aspect of the invention there is provided the use of pediococcus acidilactici as described in the first aspect above for the preparation of a product for protecting the liver.
In some embodiments of the invention, the function of the product comprises at least reducing the level of glutamic pyruvic transaminase (ALT) in serum.
In some embodiments of the invention, the product is a pharmaceutical product, feed additive, microecological preparation or a microbial agent.
In a fifth aspect of the present invention there is provided the use of pediococcus acidilactici as described in the first aspect above for the preparation of a product for the prevention and/or treatment of hyperlipidemia and/or fatty liver.
In some embodiments of the invention, the product is a pharmaceutical product, a feed additive, a microecological preparation, or a microbial agent.
In a sixth aspect of the invention, there is provided the use of pediococcus acidilactici as described in the first aspect above for the preparation of a product for reducing blood fat and increasing muscle.
In some embodiments of the invention, the functions of the product include: reducing abdominal fat rate, reducing intramuscular fat width, and improving pectoral muscle rate.
In some embodiments of the invention, the product is a pharmaceutical product, feed additive, microecological preparation or a microbial agent.
In a seventh aspect of the invention there is provided the use of pediococcus acidilactici as described in the first aspect above for the preparation of a bacteriostatic product.
In some embodiments of the invention, the bacteriostasis spectrum of the product comprises at least: coli, staphylococcus aureus, salmonella enteritidis, clostridium perfringens, serratia marcescens, bacillus circulans, streptococcus pyogenes, bacillus cereus, and pseudomonas aeruginosa.
In some embodiments of the invention, the product is a pharmaceutical product, feed additive, microecological preparation or a microbial agent.
In an eighth aspect of the present invention there is provided a product which is a pharmaceutical product, feed additive, microecological preparation or a microbial agent comprising Pediococcus acidilactici as described in the first aspect above; the product is a product with at least one of the following functions:
(1) Regulating lipid metabolism;
(2) Regulating bile acid metabolism;
(3) Protecting liver;
(4) Preventing and/or treating hyperlipidemia;
(5) Preventing and/or treating fatty liver;
(6) Lipid-lowering and muscle-increasing;
(7) Bacteriostasis; and
(8) In vitro degradation of cholesterol and/or triglycerides.
In some embodiments of the invention, the product has at least one of the following functions:
(1) Reducing the content of total cholesterol in serum;
(2) Reducing the content of triglyceride in serum;
(3) Increasing the content of high density lipoprotein cholesterol in serum;
(4) Reducing the content of fatty acid synthetase in serum;
(5) Reducing the content of hydroxymethyl glutaryl coenzyme A reductase in serum;
(6) Increasing the level of lipoprotein lipase in the serum;
(7) Increasing the content of hormone sensitive lipase in serum;
(8) Reducing the concentration of total bile acid in serum;
(9) Reducing the content of glutamic pyruvic transaminase in serum;
(10) Reducing the abdominal fat rate;
(11) Reducing the fat width between muscles; and
(12) And the pectoral muscle rate is improved.
In some embodiments of the invention, the product is a feed additive comprising the following composition: red yeast rice, xylooligosaccharide, pediococcus acidilactici and medical stone powder; for example, in one embodiment, the red yeast rice is added in an amount of 100-300g/kg, the xylooligosaccharide is added in an amount of 50-150g/kg, and the viable count of Pediococcus acidilactici is 5X 10 8 -2×10 9 cfu/g, and the balance of medical stone powder.
In some embodiments of the invention, the product is a feed comprising a basal feed and a feed additive, for example, in one embodiment, the feed additive is composed of red rice, xylooligosaccharide, pediococcus acidilactici and medical stone powder, and the addition amount of the feed additive in the feed is 1-4 per mill.
In a ninth aspect of the invention, there is provided a method comprising administering to a subject an effective amount of pediococcus acidilactici as described in the first aspect above or a product comprising said pediococcus acidilactici to achieve at least one of the following functions:
(1) Regulating lipid metabolism;
(2) Regulating bile acid metabolism;
(3) Protecting liver;
(4) Preventing and/or treating hyperlipidemia;
(5) Preventing and/or treating fatty liver;
(6) Lipid-lowering and muscle-increasing; and
(7) And (5) bacteriostasis.
Wherein the subject refers to animals which are objects of treatment, observation or experiment, preferably livestock and poultry, the livestock and poultry refer to various animals which are domesticated for a long time by labor, mainly refer to animals which are artificially raised for a long time and are widely applied in production for meeting the needs of meat, eggs, milk, fur and the like, such as livestock (such as pigs, cattle, sheep and the like), poultry (such as chickens, ducks, geese, pigeons and the like), and special livestock (such as deer, turkeys and the like).
By effective amount is meant the amount of pediococcus acidilactici described herein or the amount of a product comprising pediococcus acidilactici described herein which may elicit the biological or medical response of a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other medical staff, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition or disorder being treated.
Advantages of the present invention compared to the prior art include:
the invention provides a pediococcus acidilactici strain which has good probiotic properties and shows a plurality of excellent performances.
Specifically, the pediococcus acidilactici has strong bile salt tolerance, and the survival rate of 4 hours in 0.5% of bile salt concentration can reach 58.46%; the acid-resistant performance is good, the survival rate of the acid-resistant composite material in an environment with the pH value of 3.0 reaches 147.37 percent, and the acid-resistant composite material can survive well in artificial intestinal juice and gastric juice; the preparation has the capacity of degrading cholesterol and triglyceride, the degradation rate of the cholesterol in vitro can reach 80.41 percent, and the degradation rate of the triglyceride can reach 23.9 percent; the bacterial strain has good antibacterial performance, and has good antibacterial capability on strains such as escherichia coli, staphylococcus aureus, salmonella enteritidis, clostridium perfringens, serratia marcescens, bacillus circulans, streptococcus pyogenes, bacillus cereus, pseudomonas aeruginosa and the like.
In addition, in animal experiments, the pediococcus acidilactici can obviously reduce the abdominal fat rate and the intramuscular fat width, improve the pectoral muscle rate and show obvious lipid-lowering and muscle-increasing effects. The pediococcus acidilactici disclosed by the invention can regulate and control lipid metabolism and bile acid metabolism, prevent and/or treat hyperlipidemia and/or fatty liver and protect liver. According to the test results, the high-fat diet can obviously improve the content of triglyceride and cholesterol, and the pediococcus acidilactici can obviously reduce the content of cholesterol, triglyceride, fatty acid synthase, hydroxymethylglutaryl-CoA reductase, total bile acid and glutamic-pyruvic transaminase in serum and obviously improve the content of high-density lipoprotein cholesterol, lipoprotein lipase and hormone-sensitive lipase in serum when the high-fat diet is eaten.
The pediococcus acidilactici provided by the invention not only can be suitable for living environment in vivo, but also can stably play roles of reducing blood fat, protecting liver and the like, and has great development potential in the livestock and poultry healthy breeding industry.
Drawings
The accompanying drawings, which are included to provide a further understanding of the application and are incorporated in and constitute a part of this application, illustrate embodiments of the application and together with the description serve to explain the application and do not constitute an undue limitation to the application. Embodiments of the present application are described in detail below with reference to the attached drawing figures, wherein:
fig. 1: the OPA method determines cholesterol standard curves.
Fig. 2: the qualitative test result diagram of the Pediococcus acidilactici BLCC2-0326 cholate hydrolase is provided.
Detailed Description
The present application is further illustrated below in conjunction with specific embodiments. It should be understood that these examples are illustrative only of the present application and are not intended to limit the scope of the present application. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out under conventional conditions or under conditions recommended by the manufacturer.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The reagents or materials used in this application are all commercially available in conventional manners, and unless specifically indicated otherwise, are all used in conventional manners in the art or according to the product specifications. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present application. The preferred methods and materials described herein are presented for illustrative purposes only.
The inventor separates and discovers a new strain, which is identified as Pediococcus acidilactici, and named as Pediococcus acidilactici (Pediococcus acidilactici) BLCC2-0326, and the new strain is preserved in China center for type culture collection (CCTCC NO) of university of Wuhan in Wuhan, china, with a preservation number of CCTCC NO: m20231310.
Pediococcus acidilactici 0326 and BLCC2-0326 described in the following embodiments are both Pediococcus acidilactici (Pediococcus acidilactici) BLCC2-0326, which is abbreviated in the present invention.
Example 1In vitro Performance test of Pediococcus acidilactici 0326
1.1 determination of the degradation Rate of Pediococcus acidilactici 0326 on cholesterol by the o-Benzodicarboxaldehyde method
And (3) preparation of a reagent:
standard solution: 300 μg/mL MRS-cholesterol medium; 30.00mg of cholesterol is accurately weighed, dissolved in 5mL of absolute ethyl alcohol by heating, 0.3g of bile salt is accurately weighed, a small amount of MRS culture medium is used for complete dissolution, 0.2g of sodium thioglycolate is weighed, all three substance solutions are added into the MRS culture medium, and the volume is fixed to 100mL.
Detection liquid: 120. Mu.g/mL MRS-cholesterol medium was prepared as described above.
Blank liquid: MRS medium.
Packaging all the culture mediums, and sterilizing for later use.
Phthalic dicarboxaldehyde reagent (OPA): and (3) dissolving 10mg of phthalic dicarboxaldehyde in glacial acetic acid to a volume of 100mL, and storing in a dark place.
Mixed acid: concentrated sulfuric acid and glacial acetic acid were mixed according to 1:1 ratio, note that concentrated sulfuric acid was added to glacial acetic acid.
Drawing a standard curve: the cholesterol standard curve was plotted as in table 1, see figure 1.
TABLE 1 design of standard curve drawing for measuring cholesterol by OPA method
After the solution is fully and evenly mixed, standing for 10min at room temperature, and measuring OD 550 Values.
Determination of cholesterol degradation Rate by Pediococcus acidilactici 0326: the seed solution activated twice was inoculated into MRS-cholesterol medium with a cholesterol addition of 120. Mu.g/mL in an inoculum size of 1% (volume fraction), and three replicates were set with the unvaccinated 120. Mu.g/mL MRS-cholesterol medium as a Control (CK), and incubated at 37℃for 24 hours.
Test results: as shown in Table 2, pediococcus acidilactici 0326 has a high cholesterol degradation rate of 80.41%.
TABLE 2 degradation rate of cholesterol by Pediococcus acidilactici 0326
1.2 in vitro Triglycerides degradation Rate
triglyceride-MRS medium formulation:
tween-80 and lard were mixed in an amount of 1:5, mixing in proportion, heating and stirring until the mixture is fully dissolved, and obtaining the triglyceride micelle. Adding 0.2% sodium thioglycolate into MRS liquid culture medium, subpackaging into test tubes or centrifuge tubes, adding 6% (volume fraction) triglyceride micelle while hot, and sterilizing at 121deg.C for 30min.
Strain culture: the activated two strains were inoculated into the triglyceride-MRS medium at an inoculum size of 1% (volume fraction), and the uninoculated triglyceride-MRS medium was used as a control, while being incubated at 37℃for 48 hours.
And (3) measuring: extracting residual triglyceride in the culture medium, dissolving with absolute ethanol of the same volume, and detecting by using a Nanjing built Triglyceride (TG) test box method.
Test results: the degradation rate of the pediococcus acidilactici 0326 on the triglyceride is 23.9 percent.
1.3 qualitative detection of bile salt hydrolase production
Adding 0.3% (m/v) of sodium deoxytaurocholate, 0.2% (m/v) of sodium thioglycolate and 0.37g/L of CaCl into freshly prepared MRS agar culture medium 2 Completely dissolving, sterilizing at 121deg.C for 15min, pouring into sterile flat plate, placing sterile filter paper sheet into the flat plate after solidification, and dripping 7 μl of bacterial suspension of Pediococcus acidilactici 0326 (about 10 9 cfu/mL), 7. Mu.L of sterile phosphate buffer was added dropwise as a blank, and the plate was incubated at 37℃for 48 hours. A white precipitate around the filter paper sheet is considered to have bile salt hydrolase activity.
As a result, as shown in FIG. 2, there was a clear white precipitate around the filter paper sheet shown by Pediococcus acidilactici 0326, indicating that Pediococcus acidilactici 0326 has bile salt hydrolase activity.
Example 2Pediococcus acidilactici 0326 probiotic energy assay
2.1 bile salt tolerance test
Preparing 10% bile salt mother liquor, and sterilizing. Before inoculation, the strain is added into MRS culture medium according to different ratios, so that the final concentration of bile salt in the culture medium is respectively 0.1%, 0.3% and 0.5%, and three concentrations are parallel. The activated Pediococcus acidilactici 0326 strain is inoculated into bile salt culture media with different concentrations according to an inoculum size of 5% (volume fraction), and cultured for 4 hours at 37 ℃, and the tolerance degree of the strain under different bile salt concentrations is examined. Survival rate= (number of viable bacteria of bile salt added bacteria liquid/number of viable bacteria of initial bacteria liquid) ×100%.
TABLE 3 Pediococcus acidilactici 0326 bile salt tolerance test
As can be seen from Table 3, pediococcus acidilactici 0326 has strong bile salt tolerance, and the 4-hour survival rate can still reach 58.46% at the concentration of 0.5% bile salt.
2.2 acid resistance test
The activated Pediococcus acidilactici 0326 bacterial liquid is inoculated into MRS liquid culture media with pH values of 3.0 and 4.0 respectively according to an inoculum size of 5% (volume fraction), three parallel pH values are set for each pH value, the culture is carried out for 2 hours at 37 ℃, and the plate colony count is carried out for sampling, so that the survival rate is calculated. Survival rate= (number of viable bacteria of bacterial liquid to be tested/number of viable bacteria of initial bacterial liquid) x 100%.
TABLE 4 acid resistance test of Pediococcus acidilactici 0326
As can be seen from Table 4, pediococcus acidilactici 0326 survived at pH3.0 for 2 hours and had a survival rate of 147.37% and good acid resistance.
2.3 Pediococcus acidilactici 0326 artificial gastrointestinal fluid tolerance experiment
Preparing artificial gastric juice: pepsin 10g is added into 1000mL hydrochloric acid solution with pH of about 2.5, and the mixture is uniformly shaken, and then the microporous filter membrane is sterilized for later use.
Preparing artificial intestinal juice: taking 6.8g of monopotassium phosphate, adding 500mL of water to dissolve, adjusting the pH value to 6.8 by using 0.1mol/L NaOH solution, taking 10g of trypsin, adding a proper amount of water to dissolve, mixing the two solutions, and adding water to dilute to 1000mL to obtain the finished product.
Inoculating activated Pediococcus acidilactici 0326 bacterial liquid into artificial gastrointestinal fluid according to 10% (volume fraction), respectively culturing at 37 ℃ in parallel, treating the artificial gastric fluid for 2 hours, treating the artificial intestinal fluid for 4 hours, sampling, performing plate colony counting, and calculating the survival rate.
Survival rate= (number of viable bacteria in artificial gastrointestinal fluid to be detected/number of viable bacteria in initial bacterial fluid) ×100%.
TABLE 5 Pediococcus acidilactici 0326 artificial gastrointestinal fluid tolerance experiment
As can be seen from Table 5, pediococcus acidilactici 0326 has a survival rate of 100% in artificial intestinal juice and 43.33% in artificial gastric juice.
2.4 antibacterial Properties of Pediococcus acidilactici 0326 against various pathogenic reference bacteria
Preparing reference bacteria: respectively inoculating activated fowl escherichia coli, staphylococcus aureus, salmonella enteritidis, serratia marcescens, bacillus circulans, streptococcus pyogenes, bacillus cereus and pseudomonas aeruginosa into a TSB culture medium, and culturing at 37 ℃ for 16-18 h in a shaking way. Clostridium perfringens adopts FT culture medium, and is subjected to stationary culture at 42 ℃ for 6 hours. Gradient dilution of 9 strains to 10 respectively 6 cfu/mL。
Bacteriostasis experiment: 1mL of a reference strain broth (10) was aspirated by a punching method 6 cfu/mL) is added into a sterilization culture dish, 20mL of TSA culture medium is sucked and poured into the sterilization culture dish, shaking is carried out uniformly, the TSA culture medium is uniformly distributed and coagulated at the bottom of the dish, holes (the hole diameter of a puncher is 5 mm) are punched after coagulation, 50 mu L of Pediococcus acidilactici 0326 supernatant (centrifuged at 5000 rpm for 5 minutes) is added, three parallel bacteria inhibition zone sizes are respectively counted after overnight culture at 37 ℃.
TABLE 6 antibacterial Activity of Pediococcus acidilactici 0326 against reference bacteria (diameter of inhibition zone in mm)
As can be seen from Table 6, pediococcus acidilactici 0326 has a broad antibacterial spectrum and has a certain inhibition effect on the 9 reference bacteria.
Example 3Application of pediococcus acidilactici 0326
3.1 preparation of bacterial powder
Inoculating activated Pediococcus acidilactici 0326 twice into 5L sterilizing MRS culture medium according to 2% (volume fraction), culturing at 37deg.C for 24h, centrifuging at 5000 r for 10min, centrifuging to obtain bacterial mud, mixing 1 part bacterial mud with 6 parts lyoprotectant (composition of lyoprotectant comprises skimmed milk powder 20 parts, sucrose 5 parts and water 100 parts by mass), and vacuum lyophilizing to obtain bacterial powder with viable count of 2.0X10 11 cfu/g。
3.2 test group
After 108 AA broilers with 1 day old and healthy chickens are selected and pre-fed for one week, the chickens are divided into 3 treatment groups according to the principle of no difference in weight, 6 chickens are treated each time, the test period is 35d, basic daily ration is purchased from mountain farming and grazing (Taian) limited company, free feeding and drinking are carried out, and the body weight and the feed intake are recorded each week in a test.
The control group (CK) was fed basal diet.
Test 1 group (group Y) was fed high fat ration (basal ration +3% soybean oil).
Test group 2 (326 group) was fed with high-fat diet + Pediococcus acidilactici 0326 (Pediococcus acidilactici 0326 content in the feed was 2X 10) 7 cfu/g)。
Samples were taken at 21 and 42 days of age, with 1 chicken approaching average body weight per group. Weighing, heart sampling, centrifuging at 3000rpm for 10min at 4deg.C, separating serum, subpackaging, and preserving at-20deg.C. The neck is sacrificed by displacement, the hair is removed, the cutin is removed, the pectoral muscle, the abdominal fat, the liver and the like are completely peeled off, and the weight is measured.
3.3 index detection
3.3.1 growth Properties
The broiler chickens were weighed weekly for caking and the Average Daily Gain (ADG) and feed to weight ratio (F: G) were counted for each stage of broiler chickens.
3.3.2 slaughter Performance and visceral organ index
Carcass weight: the weight after exsanguination, removal of feathers, foot cuticle, toe shell and coracoid shell is carcass weight.
Slaughter rate (%) = carcass weight/live weight x 100%.
Full bore-free weight: the carcasses remove the weight of the trachea, esophagus, crop, adenoma stomach, myostomach, abdomen fat, intestine, spleen, pancreas, gall bladder, reproductive organs, and head and feet. Full bore removal rate (%) = full bore removal weight/live weight x 100%.
Liver index (%) =liver weight/live weight x 100%.
Abdominal fat ratio (%) =abdominal fat weight/(full clean bore+abdominal fat weight) ×100%, abdominal fat refers to abdominal fat and fat around myostomach.
Intramuscular fat width: the width of the fat around the pectoral muscle, between the left and right and middle muscles was measured with a vernier caliper, and the average value/live weight (mm/kg) was taken.
Pectoral muscle rate: the skin was cut along the sternum ridge and peeled back, and the muscle and shoulder blade tendon attached to the side of the sternum ridge were cut off with a knife, and the peeled pectoral muscle was peeled off in its entirety, and the pectoral muscle ratio=both pectoral muscles/viable weight×100%.
3.3.3 detection of biochemical indicators of blood lipid and blood
Measuring the contents of Total Cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total Bile Acid (TBA) and Cholinesterase (CHE) in serum by using a BS230 biochemical analyzer; the content of glutamic pyruvic transaminase (ALT) and glutamic oxaloacetic transaminase (AST) was determined using a kit purchased from Nanjing institute of biological engineering.
3.3.4 detection and analysis of lipid metabolism-related enzyme Activity ELISA
ELISA kits are respectively adopted to detect enzymes related to lipid synthesis in serum: fatty Acid Synthase (FAS), hydroxymethylglutaryl-coa reductase (HMGR). Lipid breakdown related enzymes: lipoprotein lipase (LPL), liver esterase (HL), hormone Sensitive Lipase (HSL), peroxisome proliferator activated receptor gamma co-stimulatory factor 1 alpha (PGC-1 alpha) content.
All the kits are purchased from Shanghai enzyme-linked organisms.
3.4 test results
3.4.1 growth Properties
Table 7 full-term growth performance of broiler chickens
Note that: the same column data in the table is marked with the same lowercase letters or no marks, the difference is not obvious (P is more than 0.05), the different lowercase letters of the table are marked with the difference (P is less than 0.05), the different uppercase letters of the table are marked with the difference (P is less than 0.01), and the table is the same.
As can be seen from Table 7, the group with Pediococcus acidilactici 0326 added had the lowest feed to meat ratio, the highest average daily gain and better growth performance, but the differences between the groups were not significant.
3.4.2 body fat and liver index of broiler chickens
Table 8 body fat and liver index of broilers
As can be seen from table 8, there was no significant difference between the liver index groups at 42 days of age; the abdomen fat rate of 326 group is reduced by 28.05 percent compared with that of Y group, which is close to that of the control group; the width of the intramuscular fat of 326 groups is significantly lower than that of 19.8% of the Y group and lower than that of 11.2% of the control group.
3.4.3 slaughtering Performance of broilers at 42 days old
Table 9 slaughter Properties of broiler chickens at 42 days old
As can be seen from table 9, there was no significant difference in the slaughter rate and total clean-bore weight of each group of broilers. The pectoral muscle rate of the group 0326 added with Pediococcus acidilactici was 4.8% higher than that of the group Y.
3.4.4 determination of blood lipid content of broiler chickens
Table 10 blood lipid content (mmol/L) of 42-day-old broiler chickens
As can be seen from Table 10, the high-fat ration (Y group) has significantly higher blood lipid levels than the CK group, and the Triglyceride (TG) and Total Cholesterol (TC) levels are increased by 27.03% and 26.52% respectively compared with the control group;
compared with the Y group, the blood lipid reducing effect is better after the lactic acid pediococcus 0326 is added in the high-fat ration, the Triglyceride (TG) content in the serum is obviously reduced by 21.27%, the Total Cholesterol (TC) content is obviously reduced by 22.34%, the HDL-C content in the serum is obviously improved by 20.11%, and the LDL-C content is reduced by 39.62%. The increase of HDL content in serum can inhibit LDL uptake by cells, thereby inhibiting accumulation of cholesterol in cells, and transferring excessive cholesterol in lipid form, thereby reducing blood lipid level.
3.4.5 serum Biochemical index determination
TABLE 11 serum Biochemical index determination results
As can be seen from table 11, the glutamic pyruvic transaminase (ALT) content of group Y was significantly higher than that of group CK 38.4% and significantly higher than that of group 326 53.37%. The 326 groups have the lowest glutamic-oxaloacetic transaminase (AST) content, and no obvious difference exists between the groups. The total bile acid concentration in group 326 serum was significantly lower than 58.32% in group Y.
AST is mainly present in the heart muscle, and then in the liver, skeletal muscle, and when AST is elevated, liver parenchyma is damaged, which is one of important indicators of liver function. ALT is mainly distributed in various cells, and is mostly present in liver cells, even if a small amount of liver cells are necrotized, ALT can be obviously increased, and is a sensitive index of liver cell damage.
Bile acid has important functions of promoting absorption of fat-soluble nutrient substances, regulating glucose and lipid metabolism, and maintaining energy balance of organism. Total Bile Acid (TBA) is a group of metabolites of cholesterol in the liver, which are the final products of cholesterol catabolism in the liver, and the intestinal wall is absorbed and returned to the liver through the portal vein for use, so the blood concentration is very low. When liver cells are diseased or blocked in the liver, bile acid metabolism is blocked and reversely flows into blood, and the concentration of total bile acid in serum is increased.
Serum total bile acid is a sensitive diagnostic index of hepatic parenchymal injury and digestive system diseases. Once liver cells have lesions or intestinal-hepatic circulatory disorders, they can cause an increase in total bile acids in the blood.
Serum Cholinesterase (CHE) activity is an important means to aid in the diagnostic assessment of hepatic parenchymal cell damage in the clinic. The fatty liver patient has obviously increased triglyceride, cholesterol and apolipoprotein B (apo-B), and serum cholinesterase is also obviously increased, which is a prominent biochemical index of the fatty liver patient.
3.4.6 fatty acid synthase and hydroxymethylglutaryl-CoA reductase assay
TABLE 12 determination of the serum FAS and HMGR content of broiler chickens (ng/mL)
FAS is one of the key enzymes for fatty acid synthesis, and is a complex system composed of a plurality of enzymes, and is obviously and positively related to the fat content of carcasses, and HMGR is a key enzyme for catalyzing cholesterol synthesis from the head in vivo, and the activity of the key enzyme directly influences the cholesterol synthesis speed and the cholesterol content in vivo.
As can be seen from table 12, both FAS and HMGR were significantly improved in the high-fat ration (group Y) compared to the CK group. Group 326 showed a reduction in both enzymes compared to group Y, a significant reduction in FAS content of 16.94% and a reduction in HMGR content of 26.24%.
3.4.7 lipid decomposition related enzyme assay
Table 13 determination of the content of enzymes involved in serum lipid decomposition of broiler chickens
As can be seen from Table 13, the LPL activity was higher in group 326 than in group Y, 23.17%; the HSL activity of group 326 is obviously higher than that of group Y57.28, which is beneficial to the decomposition of lipid in vivo and the reduction of fat deposition in vivo.
Lipoprotein lipase (LPL) is an enzyme that catalyzes the hydrolysis of protein-associated triglycerides. It is located on the luminal surface of the capillary endothelium and plays a critical role in triglyceride metabolism. The LPL activity is improved, and can reduce the levels of Total Cholesterol (TC), triglyceride (TG), serum low density lipoprotein cholesterol (LDL-C) and serum very low density lipoprotein cholesterol (VLDL-C) in serum, raise HDL-C level, and avoid hyperlipidemia and fatty liver.
Liver esterase (HL) is mainly distributed in the liver, synthesized by hepatic parenchymal cells, transported to the surface of hepatic sinusoidal endothelial cells and plays a physiological role. HL catalyzes Chylomicron (CM) and promotes triglyceride hydrolysis in VLDL. The sun's disease and the like find that the ligustrazine can raise liver lipase activity, obviously relieve steatosis, improve fat accumulation in acute liver injury fatty liver and have obvious protective effect on liver.
Hormone Sensitive Lipase (HSL) is a key enzyme and a rate-limiting enzyme for initial start of triglyceride decomposition in adipose tissue, and is responsible for decomposing triglyceride in adipose tissue to release free fatty acid, and is the most key factor for regulating the decomposition of adipose tissue, and is also one of key enzymes for influencing the fat deposition of animals.
PPARgamma coactivator 1 alpha (PGC-1 alpha) is an inducible transcriptional coactivator that can act as an intermediate regulator of promotion or inhibition by mediating various mitochondrial signaling pathways, thus having a number of specific physiological effects. PGC-1 alpha is widely distributed, is closely related to obesity, diabetes and lipid metabolism disorder, and its expression is regulated by hypoxia, hypothermia, exercise, pathological conditions and other factors.
Example 4Formulation product containing Pediococcus acidilactici 0326 and application thereof
4.1 product formulation and dosage
Product 1: red rice (200 g/kg), xylooligosaccharide (100 g/kg), pediococcus acidilactici 0326Powder and the balance of medical stone powder. The content of Pediococcus acidilactici 0326 in the product is 5×10 8 cfu/g；
Product 2: red yeast rice (200 g/kg), xylooligosaccharide (100 g/kg), pediococcus acidilactici 0326 bacterial powder and the balance of medical stone powder. The content of Pediococcus acidilactici 0326 in the product is 2×10 9 cfu/g。
The product 1 and the product 2 can be respectively added into feed for use, wherein the addition amount of the product 1 and the product 2 in the feed is 2 per mill.
The preparation method of the bacterial powder comprises the following steps: the method comprises the steps of carrying out expansion culture of Pediococcus acidilactici 0326 by an industrial 5t fermentation tank, regulating and controlling pH of the fermentation process to be 5.8-6.0 by adopting a general MRS culture medium, culturing at 36-38 ℃ for 20-22h, centrifugally harvesting bacterial sludge, mixing 1 part of bacterial sludge with 6 parts of freeze-drying protective agent (the composition of the freeze-drying protective agent is that, according to parts by mass, 20 parts of skim milk powder, 5 parts of sucrose and 100 parts of water) and carrying out vacuum freeze-drying to obtain bacterial powder, wherein the number of viable bacteria is 4.0x10 11 cfu/g。
4.2 animal test group
216 healthy yellow-feather broilers at 1 day old are selected, and after one week of pre-feeding, the yellow-feather broilers are divided into 6 treatment groups according to the principle of no difference in weight. Each treatment was repeated 6 times, 6 chickens per repetition. Test period 42d. Basal diet was purchased from mountain farming (taan) limited and feeds 510 and 511 were routinely used for broilers, free feeding and drinking water, and weekly weight and feed intake were recorded for the test.
The control group (CK) was fed with conventional basal diet.
Group D feeding basal ration plus 2 per mill viable count is 5 multiplied by 10 8 cfu/g product 1.
Group G feeding basal ration plus 2 per mill viable count is 2 multiplied by 10 9 cfu/g product 2.
Group Y was fed high fat ration (basal ration +3% soybean oil).
YD group fed with high-fat daily ration plus 2 per mill viable count of 5×10 8 cfu/g product 1.
YG group fed with high-fat ration plus 2 per mill viable count of 2×10 9 cfu/g product 2.
4.3 sample collection and detection
The chickens are weighed and sintered every week, the growth performance every week is counted, one chicken wing vein is selected for blood sampling every repeated group at 21, 35 and 49 days old respectively, serum is collected, and blood fat and serum biochemical index detection is carried out. Killing by cervical displacement, removing hair and cutin, completely peeling abdominal fat, and weighing liver. The index detection method is the same as 3.3 of the invention, wherein the content of glutamic pyruvic transaminase (ALT) and glutamic oxaloacetic transaminase (AST) is detected by a biochemical analyzer.
4.4 test results
4.4.1 test of the growth Property of broiler chickens in full-term (7-49 days old)
Table 14 test of the full-term growth performance of broilers
As can be seen from Table 14, the addition of the lipid-lowering product to the basal diet resulted in no significant difference in average daily gain and feed conversion ratio between group D and group G as compared with the Control (CK).
The lipid-lowering products are added into the high-lipid daily ration, and compared with the YD group and the YG group, the feed conversion ratio is not obviously different, but the average daily gain of the YG group is obviously higher than that of the Y group by 13.33 percent.
4.4.2 slaughtering Performance of broilers at 49 days old
Table 15 slaughter Properties of broiler chickens at 49 days old
As can be seen from table 15, the addition of the lipid-lowering product in the basal diet increases the slaughter rate, total evisceration and pectoral muscle rate of group D, group G, which are significantly higher than 1.7% of CK, and group G, which are significantly higher than 22.24% of CK, compared to the control group.
The high-fat ration is added with a lipid-lowering product, the slaughter rate of YG groups is obviously higher than that of Y groups, and compared with Y groups, the YD groups have no obvious difference in total evisceration rate and pectoral muscle rate.
4.4.3 body fat index
Table 16 visceral organ and body fat index of 49 day-old broiler chickens
As can be seen from table 16, the abdominal fat rate of broilers fed with high fat feed is obviously increased, and the Y group is obviously higher than the CK group by 40.8%.
Lipid-lowering products are added into the basic ration, the intramuscular fat width and the abdominal fat rate of the group D and the group G have a tendency to be reduced compared with those of the control group, and the difference of the groups is not obvious.
The fat-reducing products are added into the high-fat ration, and compared with the YD group and the YG group, the fat width and the fat percentage between muscles are reduced, and the fat percentage of the abdomen of the YD group is obviously lower than that of the Y group by 37.22 percent.
4.4.4 detection of 49-day-old blood fat of broiler chickens
Table 17 blood lipid content (mmol/L) of 49-day-old broiler chickens
As can be seen from table 17, the total cholesterol and triglyceride content in the serum of group D is significantly lower than 22.92% and 44.3% of CK, respectively, the high-density lipoprotein cholesterol has a tendency to increase, and the low-density lipoprotein cholesterol has a tendency to decrease, as compared with the control group, by adding the lipid-lowering product into the basic ration; group G triglyceride levels were significantly lower than control 54.43%.
Compared with Y groups, the content of TC, TG and HDL-C in YD group serum is obviously different, and the content of TG and HDL-C in YG group serum is obviously different, so that the added lipid-lowering product has obvious effect of reducing the blood lipid content of broiler chickens.
4.4.5 Biochemical detection of 49-day-old serum of broiler chickens
Biochemical detection of serum of table 18 49-day-old broiler chickens
As can be seen from table 18, by adding lipid-lowering products into the basic ration, compared with the control group, the glutamic pyruvic transaminase ALT of group G is reduced by 85.07%, the total bile acid TBA is reduced by 52.96%, the cholinesterase CHE content is reduced by 26.19%, and the average difference is obvious; compared with the control group, the cholinesterase CHE content of the group D is obviously reduced by 31.37 percent, and ALT and TBA have a reduced tendency.
Compared with Y groups, the YG group glutamic pyruvic transaminase ALT is reduced by 55.88 percent, the glutamic pyruvic transaminase AST is obviously reduced by 19.17 percent, and the total bile acid TBA content is obviously reduced by 46.27 percent. The total bile acid content of YD group is lowest and is significantly lower than that of Y group 47.26%.
The serum biochemical index values of the added lipid-lowering products are basically reduced to different degrees (compared with the corresponding control group), which shows that the added lipid-lowering products are beneficial to reducing liver injury of chickens and protecting livers.
4.4.6 determination of the FAS and HMGR content of the serum of broilers
TABLE 19 determination of the serum FAS and HMGR content of broiler chickens (ng/mL)
As can be seen from Table 19, the addition of the lipid-lowering product to the basal diet significantly reduced the Fatty Acid Synthase (FAS) in group G by 31.74% and the HMGR in group D by less than in the control group.
The lipid-lowering products are added into the high-lipid ration, and compared with the Y group, the two YD and YG groups have obviously reduced FAS and HMGR, wherein the two enzyme activities of the YD group are respectively reduced by 40.39 percent and 31.39 percent, and the YG group is respectively reduced by 45.0 percent and 33.98 percent.
4.4.7 lipid decomposition related enzyme assay
Table 20 determination of the content of lipolytic related enzymes in broiler serum
As can be seen from Table 20, the addition of lipid-lowering products to the basal diet significantly increased liver esterase HL and hormone-sensitive lipase HSL in group G compared with the control group, facilitated in vivo lipid breakdown and reduced in vivo fat deposition.
The lipid lowering products are added into the high-fat ration, and compared with the Y groups, the YD and YG groups have no obvious difference in various lipid decomposition related enzymes.
In summary, the blood lipid lowering products are added into the basic ration, and compared with the control group, the total cholesterol and triglyceride content in the serum of the added product 1 (group D) is obviously lower than 22.92 percent and 44.3 percent of the CK group respectively, the high-density lipoprotein cholesterol has a tendency to rise, the low-density lipoprotein cholesterol has a tendency to lower, and the blood lipid spectrum is better. The product 2 (group G) is added into the basic ration, so that the content of Fatty Acid Synthase (FAS) can be obviously reduced by 31.74%, and liver esterase HL and hormone sensitive lipase HSL which are beneficial to lipid decomposition are obviously improved, thereby being beneficial to in-vivo lipid decomposition and reducing in-vivo fat deposition.
The lipid-lowering products are added into the high-fat ration, and compared with the high-fat ration (Y group), the contents of TC and TG in the serum of the added product 1 (YD group) are obviously reduced, the contents of HDL-C are obviously increased, and the contents of TG and HDL-C in the serum of the added product 2 (YG group) are obviously different. Both FAS and HMGR were significantly reduced in both YD and YG groups compared to the Y group. The lipid decomposition related enzymes have no obvious difference, which indicates that the lipid synthesis is mainly influenced by the lipid-lowering product.
The blood serum biochemical index values of the added lipid-lowering product group are reduced to different degrees (compared with the corresponding control group), which shows that the added lipid-lowering product is beneficial to reducing liver injury of chickens and protecting the liver.
The specific features described in the above embodiments of the present invention may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
The foregoing description is only a preferred embodiment of the present application, and is not intended to limit the present application, but although the present application has been described in detail with reference to the foregoing embodiment, it will be apparent to those skilled in the art that modifications may be made to the technical solutions described in the foregoing embodiments, or that equivalents may be substituted for part of the technical features thereof. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application should be included in the protection scope of the present application.
Claims (23)
1. Pediococcus acidilactici, designated Pediococcus acidilactici (Pediococcus acidilactici) BLCC2-0326, which was deposited at the China center for type culture collection, university of Wuhan, gmbH, of China, at month 07, 2023, accession number: cctccc NO: m20231310.
2. Use of pediococcus acidilactici according to claim 1, for the preparation of a product for regulating lipid metabolism, wherein the subject of said use is a chicken.
3. The use according to claim 2, wherein the product is a pharmaceutical product, a feed additive, a microecological preparation or a microbial agent.
4. The use of claim 2, wherein the function of the product comprises at least one of:
(1) Reducing the content of total cholesterol in serum;
(2) Reducing the content of triglyceride in serum;
(3) Increasing the content of high density lipoprotein cholesterol in serum;
(4) Reducing the content of fatty acid synthetase in serum;
(5) Reducing the content of hydroxymethyl glutaryl coenzyme A reductase in serum;
(6) Increasing the level of lipoprotein lipase in the serum; and
(7) Increasing the content of hormone sensitive lipase in serum.
5. Use of pediococcus acidilactici according to claim 1, for the preparation of a product for regulating bile acid metabolism, wherein the subject of said use is a chicken.
6. The use according to claim 5, wherein the function of the product comprises at least a reduction of the concentration of total bile acids in serum.
7. The use according to claim 5, wherein the product is a pharmaceutical product, a feed additive, a microecological preparation or a microbial agent.
8. Use of pediococcus acidilactici according to claim 1, for the preparation of a product for protecting the liver, wherein the subject of said use is a chicken.
9. The use according to claim 8, wherein the function of the product comprises at least a reduction of the glutamic pyruvic transaminase content in the serum.
10. The use according to claim 8, wherein the product is a pharmaceutical product, a feed additive, a microecological preparation or a microbial agent.
11. Use of pediococcus acidilactici according to claim 1, for the preparation of a product for the prevention and/or treatment of hyperlipidemia and/or fatty liver, wherein the subject of said use is a chicken.
12. The use according to claim 11, wherein the product is a pharmaceutical product, a feed additive, a microecological agent or a microbial agent.
13. Use of pediococcus acidilactici according to claim 1 for the preparation of a product for reducing blood lipid and increasing muscle, wherein the subject of the use is a chicken.
14. The use of claim 13, wherein the functions of the product include: reducing abdominal fat rate, reducing intramuscular fat width, and improving pectoral muscle rate.
15. The use according to claim 13, wherein the product is a pharmaceutical product, a feed additive, a microecological preparation or a microbial agent.
16. Use of pediococcus acidilactici according to claim 1 for the preparation of a bacteriostatic product;
the bacteriostasis spectrum of the product comprises: coli, staphylococcus aureus, salmonella enteritidis, clostridium perfringens, serratia marcescens, bacillus circulans, streptococcus pyogenes, bacillus cereus, and pseudomonas aeruginosa.
17. The use according to claim 16, wherein the product is a pharmaceutical product, a feed additive, a microecological preparation or a microbial agent.
18. A product which is a pharmaceutical product, feed additive, microecological preparation or a microbial agent comprising pediococcus acidilactici as described in claim 1; the subject of the product is a chicken; the product is a product with at least one of the following functions:
(1) Regulating lipid metabolism;
(2) Regulating bile acid metabolism;
(3) Protecting liver;
(4) Preventing and/or treating hyperlipidemia;
(5) Preventing and/or treating fatty liver;
(6) Lipid-lowering and muscle-increasing;
(7) And (5) bacteriostasis.
19. The product according to claim 18, characterized in that it has at least one of the following functions:
(1) Reducing the content of total cholesterol in serum;
(2) Reducing the content of triglyceride in serum;
(3) Increasing the content of high density lipoprotein cholesterol in serum;
(4) Reducing the content of fatty acid synthetase in serum;
(5) Reducing the content of hydroxymethyl glutaryl coenzyme A reductase in serum;
(6) Increasing the level of lipoprotein lipase in the serum;
(7) Increasing the content of hormone sensitive lipase in serum;
(8) Reducing the concentration of total bile acid in serum;
(9) Reducing the glutamic-pyruvic transaminase content in serum;
(10) Reducing the abdominal fat rate;
(11) Reducing the fat width between muscles;
(12) And the pectoral muscle rate is improved.
20. The product of claim 18, wherein the product is a feed additive having a composition of: red yeast rice, xylooligosaccharide, pediococcus acidilactici according to claim 1 and medical stone powder.
21. The product according to claim 20, wherein the feed additive comprises red rice 100-300g/kg, xylooligosaccharide 50-150g/kg, and Pediococcus acidilactici with viable count of 5×10 8 -2×10 9 cfu/g, and the balance of medical stone powder.
22. The product according to claim 18, characterized in that the product is a feed comprising a basal feed and a feed additive.
23. The product of claim 22, wherein the feed additive in the feed consists of red yeast rice, xylooligosaccharide, pediococcus acidilactici and medical stone powder according to claim 1, and the addition amount of the feed additive in the feed is 1-4 per mill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311047267.1A CN116875513B (en) | 2023-08-18 | 2023-08-18 | Pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311047267.1A CN116875513B (en) | 2023-08-18 | 2023-08-18 | Pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116875513A CN116875513A (en) | 2023-10-13 |
| CN116875513B true CN116875513B (en) | 2024-01-23 |
Family
ID=88266475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311047267.1A Active CN116875513B (en) | 2023-08-18 | 2023-08-18 | Pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116875513B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117866844B (en) * | 2024-01-18 | 2024-07-09 | 朗恒科技集团有限公司 | Pediococcus acidilactici LH01 and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104388345A (en) * | 2014-11-05 | 2015-03-04 | 中国农业科学院哈尔滨兽医研究所 | New strain of pediococcus acidilactici and application thereof |
| CN107058170A (en) * | 2017-02-10 | 2017-08-18 | 中国农业大学 | Pediococcus acidilactici BCC 1 and its application of the one plant height effect using xylo-oligosaccharide |
| WO2022058798A2 (en) * | 2020-09-18 | 2022-03-24 | Biocc Oü | Microorganism strain pediococcus acidilactici tak 589 coccobest as an antimicrobial and antioxidant probiotic |
| WO2023087944A1 (en) * | 2021-11-22 | 2023-05-25 | 天津博菲德科技有限公司 | Pediococcus acidilactici for improving production performance and immune level of broilers, and screening method therefor and use thereof |
-
2023
- 2023-08-18 CN CN202311047267.1A patent/CN116875513B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104388345A (en) * | 2014-11-05 | 2015-03-04 | 中国农业科学院哈尔滨兽医研究所 | New strain of pediococcus acidilactici and application thereof |
| CN107058170A (en) * | 2017-02-10 | 2017-08-18 | 中国农业大学 | Pediococcus acidilactici BCC 1 and its application of the one plant height effect using xylo-oligosaccharide |
| WO2022058798A2 (en) * | 2020-09-18 | 2022-03-24 | Biocc Oü | Microorganism strain pediococcus acidilactici tak 589 coccobest as an antimicrobial and antioxidant probiotic |
| WO2023087944A1 (en) * | 2021-11-22 | 2023-05-25 | 天津博菲德科技有限公司 | Pediococcus acidilactici for improving production performance and immune level of broilers, and screening method therefor and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨凤.《动物营养学》.中国农业出版社,2003,全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116875513A (en) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110218681B (en) | Lactobacillus fermentum KP101 and application thereof | |
| TW201023759A (en) | Method for using a bacillus subtilis strain to enhance animal health | |
| CN116875513B (en) | Pediococcus acidilactici and application thereof in regulating lipid metabolism and protecting liver | |
| CN111690620B (en) | Clostridium welchii bacteriophage, bacteriophage composition and application thereof | |
| CN113308421B (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| CN111304119B (en) | Feeding bacillus subtilis for degrading fumonisins and application thereof | |
| CN110878266B (en) | Lactobacillus johnsonii and application thereof | |
| EP2881459A1 (en) | Novel lactic acid bacterium | |
| CN114569638A (en) | Ackermanella muciniphila microecological preparation and application thereof to laying hens | |
| Kryukov et al. | The Derivative Of Prussian Blue Paint‒Khzh-90 Cesium Isotopes’ Sorbent At Mycotoxicoses | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| CN108079023B (en) | Application of lactobacillus equi ZW3 in preparation of medicines for preventing or improving mental problems caused by stress | |
| CN114561318B (en) | Lactobacillus murinus and application thereof in treatment of type II diabetes | |
| CN115287224A (en) | Yak-derived lactobacillus reuteri for improving intestinal microbial development of indigenous animals and application thereof | |
| Shabanzadeh et al. | Growth performance, intestinal histology, and biochemical parameters of rainbow trout (Oncorhynchus mykiss) in response to dietary inclusion of heat-killed Gordonia bronchialis | |
| CN108546653B (en) | Novel lactobacillus fermentum and application thereof in feed field and sewage treatment field | |
| CN103952357B (en) | The saliva lactobacillus of a kind of efficient suppression fowl source Campylobacter | |
| RU2292156C1 (en) | Method for rearing in broilers | |
| CN106834186B (en) | Lactobacillus plantarum microecological preparation and preparation method and application thereof | |
| Lysenko et al. | Biological properties of microorganisms isolated from drone milk of honeybees | |
| CN115925832A (en) | Lactein and application thereof in preventing and controlling bacterial infection of livestock and poultry | |
| CN112617015A (en) | Feed additive composition containing hirsutella sinensis culture and preparation method thereof | |
| KR20110094871A (en) | Poultry feed additives including fermented plum by-products | |
| CN110079477A (en) | One plant of lactobacillus plantarum for preventing and treating Salmonella pullorum disease and its preparation and application | |
| CN117736941B (en) | Bacillus licheniformis King58 beneficial to canine bones and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |